Stunned! The gross profit margin of these 8 pharmaceutical companies is over 90%. What are they selling?

In recent years, A-share pharmaceutical companies are hot in the capital market, and their development speed is amazing In the first half of this year, there are 8 listed pharmaceutical companies with a gross profit rate of more than 90% What products can they sell with such a high gross profit rate? Table 1: a list of 8 listed pharmaceutical companies with a gross profit rate in the first half of 2017 (unit: 100 million yuan) none = "shifumousedownstyle ('shifu bus_002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of our company: dust mite drops Table 2: main product performance of our company in the first half of 2017 (unit: 10000 yuan) Our company's main business is biopharmaceutical The products approved for marketing include dust mite drops (trade name: Changdi) and dust mite skin prick diagnostic kit (trade name: Changdian) In the first half of the year, the company's operating revenue was 16.51329 million yuan, an increase of 23.77% year on year; the net profit attributable to the common shareholders of the listed company was 78.7301 million yuan, an increase of 45.45% year on year The main reason for the increase in performance is that the products have covered more than 30 provinces, cities and autonomous regions in the country, won the bid in the centralized purchase of drugs in most provincial medical institutions, and the sales network has entered most provincial cities and some Prefecture and county-level cities in the country, with the scale of patients expanding At present, there are only three kinds of desensitization drugs approved for marketing in China, including dust mite drops, house dust mite allergens and mite allergen injection The dust mite drops have the advantages of high safety, simple operation and easy to carry Since 2012, the product has ranked first in the market share of dust mite desensitizing drugs   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of Beida pharmaceutical industry: cetinil hydrochloride Table 3: performance of main products of Beida pharmaceutical industry in the first half of 2017 (unit: 10000 yuan) In 2011, the national first-class new drug ektinib (trade name: Kemena) independently researched and developed by Beida Pharmaceutical Co., Ltd obtained the new drug certificate and production approval issued by CFDA and began to be put on the market, bringing rapid growth to the company's revenue and profit, and becoming the main source of its revenue and profit In the first half of 2017, the sales volume increased by 55.86% year-on-year It is worth mentioning that in February this year, when the national health insurance catalog was released, Kemena successively implemented the national health insurance negotiation price in most regions, and the product price was greatly reduced, while the implementation of the national health insurance catalog in various provinces and cities is still in progress Beida pharmaceutical said that the increase of sales volume of Kemena gradually reflected that from the perspective of monthly sales growth, it initially showed the effect of volume price conversion In addition, in view of the successive implementation of medical insurance in various provinces and cities, we should focus on the implementation of convergence to lay the foundation for the sales of Kemena in the second half of the year   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of Haite biology: rat nerve growth factor for injection Table 4: performance of main products of Haite biology in the first half of 2017 (unit: 10000 yuan) Haite biological is mainly engaged in the research, development, production and sales of biological products (injection of mouse nerve growth factor freeze-dried powder injection, injection of anti HBV transfer factor freeze-dried powder injection), thrombin and other chemicals Rat nerve growth factor for injection (trade name: Jinlujie), the leading product of Haite biology, is a new kind of national biological product, and the first drug for nerve injury disease approved by the government to be listed in the world It is understood that the project originated from the achievements of the 1986 Nobel Prize for physiological medicine The company has successfully transformed its research achievements in the past 50 years into industrial products, and obtained the key support from the national Torch Program and the national innovation fund program In recent years, the sales of Jinlujie has maintained a steady growth, with 766.3105 million yuan in 2016 and 386.7064 million yuan in the first half of 2017   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of shutaishen: rat nerve growth factor for injection, compound polyethylene glycol electrolyte powder (IV) table 5: performance of main products of shutaishen in the first half of 2017 (unit: 10000 yuan) Shutaishen's main products are innovative biological drug injection rat nerve growth factor (trade name: sulithin) and national exclusive product compound polyethylene glycol electrolyte powder (IV) (trade name: shutaiqing) It is understood that supithin is the first national drug approved brand product in the field of rat nerve growth factor for injection in China, leading the similar products to go on the market first, and the first to complete the phase IV clinical trial after the product goes on the market In order to continue to expand the clinical application field of supishan, the company has continuously developed and expanded new indications and obtained the clinical approval documents of new indications of "diabetic foot" and "traumatic peripheral nerve injury" of supishan in 2016 Shutaiqing, as a drug in line with the international "gold standard for clearing intestines and treating constipation", is the first-line drug in the "guidelines for the preparation of Chinese digestive endoscopy diagnosis and treatment of intestinal tract" and "guidelines for the diagnosis and treatment of chronic constipation in China" In recent years, the sales performance of the product has been growing rapidly, becoming the first brand of polyethylene glycol products, ranking first in the market share in the field of sausage   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of Zhenghai biology: oral repair film and biofilm table 6: performance of main products of Zhenghai biology in the first half of 2017 (unit: 10000 yuan) Zhenghai biological's main business is the research and development, production and sales of biological regeneration materials Its main products include oral repair film, biological film and bone repair materials Its products are the third category of implantable medical devices, while oral repair film and biological film are the main sources of income   It is understood that the product of Zhenghai biological uses tissue engineering technology, through a series of treatment such as acellularization, virus and pathogen inactivation of specific tissues of animal origin, to obtain scaffold materials with natural tissue space structure The product has good histocompatibility, no immune rejection, and can guide tissue regeneration while replacing pathological tissue, which has been widely used It is widely used in stomatology, neurosurgery and other fields In addition, Zhenghai biology has a wealth of products under research, among which active biological bone, guided tissue regeneration membrane, tissue regeneration membrane are in the clinical trial stage   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of Eide biology: EGFR gene series products, KRAS gene series products, ALK gene series products Table 7: performance of major products of Eide biology in the first half of 2017 (unit: 10000 yuan) The main business of Eide biology is the research and development, production and sales of molecular diagnosis products of tumor precision medicine, and provides relevant testing services Its molecular diagnostic reagents are aimed at EGFR, KRAS, BRAF, EML4-ALK, PIK3CA, ros1 and other gene loci, which are the most important in cancer precision medicine There are 14 independent or joint detection reagents Continuous technological innovation is the core driving force for the development of ADE biology, which attaches great importance to independent research and development and innovation The company launched the cooperation project of EGFR gene mutation blood detection for lung cancer with bringer Ingelheim, the cooperation with Beihai Kangcheng (Beijing) Pharmaceutical Technology Co., Ltd on the research and development of can008 accompanied diagnostic biomarker detection kit project, and the cooperation with Baiji Shenzhou (Beijing) Biological Technology Co., Ltd on the BRCA detection of patients in the clinical research of parpi targeted drug bgb-290   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main products of Zhifei biology: Class II seedlings of independent products table 8: performance of main products of Zhifei biology in the first half of 2017 (unit: 10000 yuan) Zhifei biological's main business income mainly comes from the sales of class II vaccines It is worth mentioning that the uncertainties caused by the events in the vaccine industry last year are gradually eliminated, the new policies of the industry have been gradually implemented, and the sales of class II vaccines have been resumed In the first half of the year, the operating revenue was 445.1620 million yuan, an increase of 142.01% year on year; the net profit attributable to the shareholders of the listed company was 171.7901 million yuan, an increase of 1326.96% year on year It is understood that there are five kinds of Zhifei biological products on sale, including AC Hib vaccine, acyw135 cerebrospinal fluid polysaccharide vaccine, Hib vaccine, AC cerebrospinal fluid polysaccharide combined vaccine and micro card Three kinds of promotion or agent products are on sale, namely, Zhejiang Pukang's live attenuated hepatitis A vaccine, MSD's 23 valent pneumonia and inactivated hepatitis A vaccine   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; b